Why the study?
Does the 20210 A allele of the prothrombin gene increase the risk of venous thrombosis in Swedish outpatients?
Does the 20210 A allele of the prothrombin gene increase the risk of venous thrombosis in Swedish outpatients?
The 20210 A allele of the prothrombin gene is a significant independent risk factor for deep venous thrombosis.
Answers are grounded in this paper and cite their sources.
Supports 20210A as independent venous thrombosis risk factor in outpatients; extends prior reports but leaves open screening utility.
A dimorphism in the 3'-untranslated region of the prothrombin gene (G to A transition at position 20210) has recently been reported to be associated with increases in plasma prothrombin levels and in the risk of venous thrombosis. We have examined the prothrombin dimorphism among 99 unselected outpatients with phlebography verified deep venous thrombosis, and in 282 healthy controls. The prevalence of the 20210 A allele was 7.1% (7/99) in the patient group, and 1.8% (5/282) in the healthy control group (p = 0.0095). The relative risk of venous thrombosis was calculated to be 4.2 (95% CI, 1.3 to 13.6), and was still significant when adjustment was made for age, sex and the factor V:R506Q mutation causing APC resistance [odds ratio 3.8 (95% CI, 1.1 to 13.2)]. As previously reported, 28% of the patients were carriers of the factor V:R506Q mutation. Thus, 34% (one patient carried both traits) of unselected patients with deep venous thrombosis were carriers of an inherited prothrombotic disorder. To sum up, our results confirm the 20210 A allele of the prothrombin gene to be an important risk factor for venous thrombosis.
No takes yet. Share an insight, caveat, or question.
Hillarp et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: